Dihydrotestosterone (DHT), Percent Free Dialysis is a laboratory measurement used to assess the bioavailable portion of dihydrotestosterone (DHT) in the bloodstream. DHT is a potent androgen hormone derived from testosterone through the action of the enzyme 5a-reductase. This conversion primarily takes place in target tissues, such as the skin, prostate, and hair follicles, and DHT plays a crucial role in male sexual development and secondary sexual characteristics.
What is DHT?
Dihydrotestosterone is one of the most powerful androgens, even more potent than testosterone itself. Its effects include:
- Development of male genitalia during fetal development
- Growth of body hair and facial hair
- Sebaceous gland activity
- Contribution to male-pattern baldness
- Influence on prostate growth
DHT acts by binding to androgen receptors in target tissues, influencing cellular activity and gene expression.
Why Measure DHT, Percent Free Dialysis?
The DHT, Percent Free Dialysis test specifically measures the fraction of circulating DHT that is not bound to proteins like sex hormone-binding globulin (SHBG). Most DHT in the blood is tightly bound to SHBG, rendering it biologically inactive. However, the free fraction (DHT not bound to SHBG) represents the bioavailable DHT - the portion of the hormone that can actively interact with cells and tissues.
This measurement is critical because only the free fraction of DHT is available to exert its physiological effects. Assessing the free fraction of DHT provides a more accurate reflection of how much of the hormone is available to the body, which can be useful in diagnosing certain hormonal disorders and assessing androgen utilization.
Clinical Applications:
The DHT, Percent Free Dialysis test is particularly important for diagnosing and evaluating conditions related to androgen metabolism, including:
5a-Reductase Deficiency:
This genetic condition involves a deficiency of the enzyme that converts testosterone to DHT. Individuals with this condition may present with ambiguous genitalia or underdeveloped male genitalia despite normal or elevated testosterone levels. Measuring DHT levels, especially the free fraction, helps to confirm the diagnosis.
Androgen Utilization Disorders:
Conditions where the body either underutilizes or overutilizes androgens can be better understood through this test. For instance, in cases of androgen insensitivity syndrome, where the body does not respond to DHT effectively, free DHT levels may still be normal or elevated.
Monitoring Androgen Replacement Therapy:
In patients undergoing testosterone replacement therapy, evaluating DHT levels helps ensure that excessive DHT, which can contribute to side effects like prostate enlargement or hair loss, is not being produced.
How is the Test Performed?
The DHT, Percent Free Dialysis test is typically conducted using a method known as equilibrium dialysis. This process involves separating the free hormone from the protein-bound hormone in a sample of blood. The percentage of free DHT is then calculated, providing insight into the bioavailable fraction of the hormone.
Conclusion
The DHT, Percent Free Dialysis test is a valuable tool for understanding androgen physiology and diagnosing conditions such as 5α-reductase deficiency. By assessing the bioavailable fraction of DHT, this test offers crucial insights into the body's hormonal balance and can guide the management of various disorders related to androgen metabolism.
References:
Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012). The 5 alpha-reductase isozyme family: A review of basic biology and their role in human diseases. Advances in Urology, 2012, Article ID 530121. https://doi.org/10.1155/2012/530121
Hoffman, R. M. (2020). Clinical practice. Screening for prostate cancer. New England Journal of Medicine, 382(11), 1076-1078. https://doi.org/10.1056/NEJMcp1905812
Rossi, A., Cantisani, C., Melis, L., Iorio, A., & Scali, E. (2021). Finasteride and dutasteride in androgenetic alopecia: A review. Dermatologic Therapy, 34(1), e14591. https://doi.org/10.1111/dth.14591
Libianto, R., Norman, R. J., & Cassar, S. (2021). Androgens and polycystic ovary syndrome: Pathophysiology and implications for clinical management. Human Reproduction Update, 27(5), 707-732. https://doi.org/10.1093/humupd/dmab008
Stout, S. M., & Stumpf, J. L. (2010). Finasteride treatment of hair loss in women. The Annals of Pharmacotherapy, 44(6), 1090-1097. https://doi.org/10.1345/aph.1M684
Gupta, A. K., & Charrette, A. (2014). The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia. Journal of Cutaneous Medicine and Surgery, 18(6), 356-363. https://doi.org/10.2310/7750.2014.14118
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.